#HRpositivebreastcancer
LightNews LightNews
oncodaily.bsky.social
Excited to have another therapeutic option to treat advanced HR+ breast cancer - Stephanie Graff
@drsgraff.bsky.social
@fda.gov

oncodaily.com/insight/step...

#BreastCancer #Cancer #DatopotumabDeruxtecan #FDA #HRpositiveBreastCancer #OncoDaily #Oncology #Health #TargetedOncology #Medicine
Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer - OncoDaily
Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer / Breast Cancer, cancer, Datopotumab deruxtecan, FDA, HR+
oncodaily.com
January 19, 2025 at 4:54 PM
4040rec.bsky.social
#oncology #breastcancer #NHS #capivasertib #Truqap #AstraZeneca #targetedtherapy #AKT #AKTinhibitors #ATKKinases #HRpositivebreastcancer #HER2negativebreastcancer #PIK3CAgene #AKT1gene #PTENgene #NICE #NICEguidance #genetictesting #BreastCancerNow
www.bbc.co.uk/news/article...
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 10:20 AM
onclive.bsky.social
The combination of giredestrant + palbociclib produced a numerical PFS improvement in patients with ER-positive/HER2-negative advanced breast cancer. 📊🧬
Read more ➡️ www.onclive.com/view/giredes...
#ASCO26 #BreastCancer #HRPositiveBreastCancer #ERPositive #CDK46 #Oncology #bcsm
Giredestrant Plus Palbociclib Yields Numerical PFS Benefit in ER+, HER2– Advanced Breast Cancer | OncLive
Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.
www.onclive.com
June 2, 2026 at 10:17 PM
seldon-dengyue.bsky.social
🎉 NMPA Approval!
#Bireociclib Tablets (#Xuan Yuening) by #Xuanzhu Biopharmaceutical Co., Ltd. are now approved for HR+/HER2– advanced or metastatic breast cancer.

📧 info@dengyuemed.com
#CDK46Inhibitor #HRPositiveBreastCancer #HER2NegativeBreastCancer #NMPAApproval
#HongKongDengYueMedicine
November 7, 2025 at 3:41 AM